SENTINEL LYMPH NODE BIOPSY:
PROCEDURE, RESULTS, AND WHAT THEY MEAN
SLNB transformed cancer staging โ replacing full lymph node dissection with a targeted, minimally invasive biopsy that achieves equivalent staging accuracy with far lower morbidity.
analyticsAt a Glance
- check_circleIdentifies the first lymph node draining the tumour โ the most likely to harbour cancer
- check_circleNegative SLNB spares patients full axillary or groin dissection and its complications
- check_circleStandard of care for early breast cancer, melanoma, endometrial cancer, and others
- check_circlePerformed by surgical oncologists at leading centres in India and China
What Is Sentinel Lymph Node Biopsy?
Lymphatic vessels carry fluid from tissues to regional lymph nodes. When cancer cells spread beyond the primary tumour, they travel through these same vessels โ typically reaching the first lymph node in the draining chain before spreading further. This first node is the sentinel lymph node.
โThe sentinel node is the gatekeeper โ if it is negative, the entire downstream node basin is almost certainly negative too. SLNB is the most efficient way to make that determination.โ
How the Sentinel Node Is Identified
A blue dye (isosulfan blue or patent blue), a radiotracer (technetium-99m colloid), or fluorescent tracer (indocyanine green/ICG) โ or a combination โ is injected near the tumour before or during surgery. The tracer travels through the lymphatics and concentrates in the sentinel node(s), which are identified by gamma probe, direct visualisation, or near-infrared camera.
Pathological Analysis
The sentinel node is sent for intraoperative frozen section (for immediate result) or paraffin-embedded histology (definitive result). If the node contains cancer cells โ either by H&E staining or immunohistochemistry โ it is positive. Pathological assessment determines whether metastasis is isolated tumour cells (ITC), micrometastasis (0.2โ2 mm), or macrometastasis (>2 mm).
SLNB by Cancer Type: When and How It Is Used
SLNB is applied across multiple solid tumours โ each with specific technical considerations and different implications of a positive result.
| Cancer Type | Node Basin | Indication | If SLNB Positive |
|---|---|---|---|
| Breast cancer (early) | Axillary nodes | cT1โT2 N0 (clinically node-negative); after neoadjuvant in selected patients | Z0011: no AXND if โค2 positive SLN + BCT + RT; AXND for โฅ3 nodes or mastectomy in most guidelines |
| Melanoma | Regional (axilla, groin, neck depending on site) | Primary melanoma >0.8 mm Breslow depth or <0.8 mm with high-risk features | MSLT-II: completion ALND not required; improves staging but no OS benefit from completion; systemic adjuvant therapy guided by node status |
| Endometrial cancer | Pelvic ยฑ para-aortic nodes | Early-stage (cT1) endometrial cancer; ICG SLNB via cervical injection is standard at experienced centres | Upstaging to IIIC; guides adjuvant chemotherapy and/or radiotherapy decision |
| Vulvar cancer | Inguinal/femoral nodes | T1โT2 squamous cell carcinoma; GROINSS-V established SLNB safety for unifocal tumours โค4 cm | Completion inguinofemoral lymphadenectomy ยฑ adjuvant RT |
| Penile cancer | Inguinal nodes | T1G2 or higher; clinically N0 โ dynamic sentinel node biopsy (DSNB) | Completion radical inguinal lymphadenectomy |
| Thyroid cancer | Central neck (Level VI) | Intermediate risk PTC; SLNB not universally adopted but used at select centres | Central compartment dissection; guides RAI decision |
The SLNB Procedure: Step by Step
SLNB is typically performed under general anaesthesia at the time of the primary tumour resection โ taking an additional 30โ60 minutes.
- 1
Tracer Injection
Blue dye, radiotracer (Tc-99m), or ICG is injected peritumorally or subdermally โ typically 30โ60 minutes before surgery for radiotracer to allow lymphatic transit. For breast cancer, dual mapping (blue dye + radiotracer or ICG) is standard, improving sentinel node identification rates to >95%.
- 2
Sentinel Node Identification
The surgeon uses a handheld gamma probe (for radiotracer), direct visual identification (for blue dye), or near-infrared camera (for ICG) to locate the sentinel node(s) in the draining lymph node basin. Nodes with radioactive counts >10% of the hottest node are harvested.
- 3
Sentinel Node Excision
Typically 1โ4 sentinel nodes are identified and excised through a small incision. The wound is closed with absorbable sutures. Frozen section analysis may provide an intraoperative result within 30 minutes โ guiding whether to proceed to immediate axillary clearance.
- 4
Pathological Assessment
The sentinel node(s) undergo haematoxylin and eosin (H&E) staining and, in many protocols, cytokeratin immunohistochemistry to detect micrometastases and isolated tumour cells that H&E alone may miss.
- 5
Result Communication and Next Decision
The pathology result is communicated within 3โ7 days. A negative result typically ends nodal surgery โ no further lymph node dissection is required. A positive result triggers a tumour board discussion to determine whether completion lymph node dissection, adjuvant therapy, or surveillance is the appropriate next step.
SLNB vs Axillary Lymph Node Dissection (ALND): Why SLNB Changed Practice
Before SLNB, all breast cancer and melanoma patients underwent full axillary or groin lymph node dissection for staging โ with significant morbidity. SLNB replaces dissection in node-negative patients with equivalent staging accuracy.
SLNB Advantages
- Equivalent staging accuracy for N0 patientsFalse-negative rate of 5โ10% is clinically acceptable given the survival equivalence demonstrated in NSABP B-32 and ACOSOG Z0011
- Dramatically lower lymphoedema riskSLNB lymphoedema rate 3โ5% vs 15โ25% with ALND โ a major quality-of-life improvement
- Shorter operation, faster recoverySLNB adds 30โ60 minutes to primary surgery; ALND adds significantly more operative time and 1โ2 additional hospital days
- Equivalent survival โ NSABP B-32 confirmed10-year overall survival and disease-free survival equivalent between SLNB and ALND for node-negative breast cancer
When ALND Is Still Required
- SLNB positive with โฅ3 involved nodes (breast)ACOSOG Z0011 criteria not met โ ALND required for adequate regional staging and control
- Clinically node-positive at presentation (cN+)SLNB is not standard for patients with palpable axillary nodes โ ALND is the standard nodal staging approach
- Inflammatory breast cancerSLNB is not appropriate โ ALND after neoadjuvant chemotherapy is standard
- Melanoma: completion lymphadenectomy after positive SLNBMSLT-II showed no OS benefit from completion ALND but regional control improved โ decision now made on individual risk-benefit assessment
SLNB: Accuracy and Outcome Data
- >95%Sentinel Node Identification RateWith dual mapping (radiotracer + blue dye/ICG) at experienced centres
- 5โ10%False-Negative RateClinically acceptable โ equivalent survival to ALND confirmed in NSABP B-32
- 3โ5%Lymphoedema Rate โ SLNBvs 15โ25% with full ALND โ major quality-of-life advantage
- Equivalent10-Year OS โ SLNB vs ALND (NSABP B-32)No survival difference between SLNB alone and ALND for node-negative breast cancer
Understanding Your SLNB Result
The pathology report from your SLNB will classify any cancer found in the sentinel node by the size and pattern of tumour deposits โ each category has different clinical implications.
Negative SLNB
No cancer cells in the sentinel node(s). This means your regional lymph nodes are almost certainly cancer-free โ no further nodal surgery is required. Your staging is confirmed as node-negative (pN0), which typically means a lower stage and reduced indication for aggressive adjuvant chemotherapy.
Positive SLNB: ITC, Micrometastasis, Macrometastasis
Isolated tumour cells (pN0(i+), โค0.2 mm): usually no further nodal surgery; significance debated. Micrometastasis (pN1mi, 0.2โ2 mm): staging upgraded; adjuvant therapy implications. Macrometastasis (pN1, >2 mm): node-positive staging confirmed; adjuvant therapy indicated; completion dissection discussed based on number of involved nodes and tumour type.
Related Surgical Oncology Guides
More in-depth resources on cancer surgery decisions.
Frequently Asked Questions
Sentinel Lymph Node Biopsy
Is SLNB painful?
The tracer injection before surgery can be mildly uncomfortable โ particularly the blue dye injection, which causes a stinging sensation. The biopsy itself is performed under general anaesthesia, so there is no pain during the procedure. Post-operatively, patients typically experience mild tenderness and bruising at the biopsy site for 1โ2 weeks. The blue dye will temporarily colour your urine and skin blue โ this is normal and resolves within 24โ48 hours.
Can SLNB miss cancer in the lymph nodes?
SLNB has a false-negative rate of approximately 5โ10% โ meaning a small number of patients with node-positive disease will have a negative SLNB result. Clinical trials (NSABP B-32, ACOSOG Z0011) have demonstrated that this false-negative rate does not adversely affect long-term survival when patients are treated appropriately with adjuvant systemic therapy and radiotherapy. At experienced centres with dual mapping (radiotracer + ICG), false-negative rates are at the lower end of this range.
If my sentinel node is positive, do I automatically need full lymph node dissection?
Not necessarily. The landmark ACOSOG Z0011 trial showed that for breast cancer patients with 1โ2 positive sentinel nodes treated with breast-conserving surgery plus whole-breast radiotherapy, completion axillary lymph node dissection (ALND) did not improve survival โ and is no longer routinely recommended in this setting. For patients with โฅ3 positive sentinel nodes, mastectomy, or inflammatory breast cancer, ALND remains the standard. For melanoma, the MSLT-II trial showed completion ALND does not improve overall survival after positive SLNB. Each case should be discussed by a multidisciplinary tumour board.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Sentinel Node Biopsy or Lymph Node Staging?
Upload your imaging and surgical records. Our team can review your nodal staging, advise on SLNB vs ALND decisions, and connect you with subspecialty surgical oncologists in India or China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.